These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 23428505)

  • 1. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
    Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
    Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging.
    Ohtsuka C; Sasaki M; Konno K; Kato K; Takahashi J; Yamashita F; Terayama Y
    Parkinsonism Relat Disord; 2014 Jul; 20(7):755-60. PubMed ID: 24768616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus.
    Shibata E; Sasaki M; Tohyama K; Otsuka K; Endoh J; Terayama Y; Sakai A
    Biol Psychiatry; 2008 Sep; 64(5):401-6. PubMed ID: 18452894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
    Kashihara K; Shinya T; Higaki F
    J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy.
    Matsuura K; Maeda M; Yata K; Ichiba Y; Yamaguchi T; Kanamaru K; Tomimoto H
    Eur Neurol; 2013; 70(1-2):70-7. PubMed ID: 23796701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach.
    Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X
    Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI.
    Liu Q; Wang P; Liu C; Xue F; Wang Q; Chen Y; Hou R; Chen T
    BMC Neurol; 2023 Aug; 23(1):301. PubMed ID: 37580712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.
    Ogisu K; Kudo K; Sasaki M; Sakushima K; Yabe I; Sasaki H; Terae S; Nakanishi M; Shirato H
    Neuroradiology; 2013 Jun; 55(6):719-24. PubMed ID: 23525598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtypes evaluation of motor dysfunction in Parkinson's disease using neuromelanin-sensitive magnetic resonance imaging.
    Xiang Y; Gong T; Wu J; Li J; Chen Y; Wang Y; Li S; Cong L; Lin Y; Han Y; Yin L; Wang G; Du Y
    Neurosci Lett; 2017 Jan; 638():145-150. PubMed ID: 27993708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.